Robert Malone on myocarditis: what the evidence says · JRE #1757

What the evidence says 01 / RECORD

Malone's approximately 27% mortality figure reflects older case series of severe or fulminant myocarditis of varied (often non-vaccine, non-adolescent) etiology, not the population actually affected by COVID-19 vaccine-associated myocarditis. A 2023 systematic review and meta-analysis in JAMA Pediatrics pooling data on myopericarditis following mRNA COVID-19 vaccination in adolescents and young adults (854 individuals across 23 studies) found that although 92.6% of patients were hospitalized and 23.2% required ICU admission, no patients died or required mechanical circulatory support, and median hospital stay was 2.8 days. A 2023 consensus statement from the Studies Committee of the Portuguese Society of Cardiology similarly concluded that while isolated case reports of fulminant post-vaccination myocarditis exist, death attributable to vaccine-associated myocarditis "remains an exception" across the published literature. The typical course in this population is mild and self-limited with rapid resolution of symptoms, in contrast to the general medical literature on severe fulminant myocarditis of mixed causes (often viral, autoimmune, or toxin-related in adults), from which historic mortality estimates in the 20-30% range originate. Applying a fulminant-myocarditis mortality rate from that unrelated literature to describe the risk of vaccine-associated myocarditis in adolescent boys misrepresents the current evidence base, which shows no observed in-hospital deaths in this specific population.